Morningstar

State Street® SPDR® S&P® Pharmaceuticals ETF XPH

Morningstar Medalist Rating
Medalist Rating as of | See State Street Investment Hub

Morningstar’s Analysis XPH

Will XPH outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

  • Process Pillar

    The Process Pillar is our assessment of how sensible, clearly defined, and repeatable XPH’s performance objective and investment process is for both security selection and portfolio construction.

  • People Pillar

    The People Pillar is our evaluation of the XPH management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.

  • Parent Pillar

    The Parent Pillar is our rating of XPH’s parent organization’s priorities and whether they’re in line with investors’ interests.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

State Street® SPDR® S&P® PhrmctlsETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

by Morningstar Automated Analysis
Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings XPH

More XPH Holdings
  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 26.3
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Supernus Inc

3.72 18M
Healthcare

Xeris Biopharma Holdings Inc

2.78 13M
Healthcare

Veradermics Inc

2.78 13M
Healthcare

Pacira BioSciences Inc

2.63 13M
Healthcare

Eli Lilly and Co

2.60 12M
Healthcare

Amneal Pharmaceuticals Inc Ordinary Shares - Class A

2.43 12M
Healthcare

Maze Therapeutics Inc

2.42 12M
Healthcare

Viatris Inc

2.38 11M
Healthcare

Zoetis Inc Class A

2.34 11M
Healthcare

Royalty Pharma PLC Class A

2.27 11M
Healthcare

Sponsor Center